CD8A and neoplasm: It aims to boost the activity of natural killer (NK) cells and cytotoxic CD8+ T lymphocytes (CTLs), as opposed to immunosuppressive cells such as mesenchymal-derived suppressor cells (MDSCs), regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and cancer-associated fibroblasts (CAFs) (53).